Civitas Therapeutics Obtains $55,000,000 Series C Financing
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ea158a22-3e53-491a-a7a1-12a9008efa06
Date 8/25/2014
Company Name Civitas Therapeutics
Mailing Address 190 Everett Ave. Chelsea, MA 02150 USA
Company Description Civitas is a pharmaceutical company focused on developing products with a clinically proven dry powder pulmonary delivery platform. The proprietary dry powder and device combination is unique in its ability to deliver a large, precise dose independent of inspiratory flow rate from a simple, passive device.
Proceeds Purposes The proceeds from this financing round will be used towards the upcoming Phase 3 clinical trials for our lead candidate, CVT-301, an inhaled formulation of levodopa (L-dopa) being developed for rapid and reliable relief from debilitating motor fluctuations, known as OFF episodes, associated with Parkinson’s disease (PD), as well as for the development of additional, early stage pipeline programs.